QIAstat-Dx胃肠道panel 2检测艰难梭菌的性能评估:与多种商业检测方法的比较
该研究以290份临床标本评估QIAstat-Dx多重胃肠道panel 2检测艰难梭菌的分析性能,并与四种商业核酸扩增检测及一种免疫assay比较。QIAstat-Dx GIP 2与各NAAT的阳性符合率(PPA)为88.5%–95.0%,阴性符合率(NPA)为96.6%–99.1%,性能与其他NAAT相当,且检测设置时间短,有利于实验室粪便检测流程。
要点
- QIAstat-Dx GIP 2检测艰难梭菌与四种商业NAAT的PPA均大于85%,NPA均大于96%。
- 与Cepheid Xpert、BD MAX、Verigene CDF、BioFire GI panel的PPA分别为95.0%、88.5%、98.1%、93.7%。
- 与上述四种NAAT的NPA分别为98.2%、96.9%、96.6%、99.1%。
核心结论
- QIAstat-Dx GIP 2检测艰难梭菌准确,性能与其他商业NAAT方法相当。
研究设计与样本
- 研究纳入290份临床标本,评估QIAstat-Dx多重胃肠道panel 2检测艰难梭菌的分析性能。
- 对照方法为四种商业NAAT(Cepheid Xpert C. difficile、BD MAX Cdiff、Verigene CDF、BioFire GI panel)及艰难梭菌免疫assay。
- 计算所有检测方法的阳性符合率(PPA)和阴性符合率(NPA)。
主要发现
- 所有分子检测方法相互比较时PPA大于85%,NPA大于96%。
- QIAstat-Dx GIP 2与Cepheid Xpert C. difficile、BD MAX Cdiff、Verigene CDF、BioFire GI panel的PPA分别为95.0%、88.5%、98.1%、93.7%。
- QIAstat-Dx GIP 2与上述四种NAAT的NPA分别为98.2%、96.9%、96.6%、99.1%。
- BioFire GI panel的PPA最高(90–100%),其次为QIAstat-Dx(88–98%)、BD MAX(87–98%)、Xpert assays(86–96%)。
关键数值与推荐
- QIAstat-Dx GIP 2与四种NAAT比较的PPA范围为88.5%–98.1%,NPA范围为96.6%–99.1%。
- 所有分子检测方法相互比较的PPA大于85%,NPA大于96%。
- BioFire GI panel的PPA为90–100%,QIAstat-Dx为88–98%,BD MAX为87–98%,Xpert assays为86–96%。
临床怎么用
- QIAstat-Dx GIP 2可用于临床标本中艰难梭菌的核酸检测,结果与其他商业NAAT可比。
- 其短检测设置时间有助于简化实验室粪便检测工作流程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute gastroenteritis is caused by a variety of pathogens, including bacteria, viruses, and parasites, which may have overlapping clinical signs and symptoms. Community-acquired gastroenteritis is caused by various pathogens, while healthcare-associated gastroenteritis is caused by Clostridioides difficile. Current diagnostic approaches utilize C. difficile nucleic acid amplification tests (NAATs) alone or in combination with an enzyme immunoassay for C. difficile antigen and toxin. This study evaluates the analytical performance of C. difficile target detection from 290 clinical specimens using the QIAstat-Dx multiplex gastrointestinal panel (GIP) 2 compared with four commercially available NAATs (Cepheid Xpert C. difficile, BD MAX Cdiff, Verigene CDF, and BioFire GI panel) as well as the C. difficile immunoassay. The positive percent agreement (PPA) and negative percent agreement (NPA) were calculated for all assays in the study. All molecular assays demonstrated a PPA greater than 85%, and an NPA greater than 96% when compared to the other NAATs. The QIAstat-Dx GIP 2 performance was comparable to the other NAATs, demonstrating 95.0%, 88.5%, 98.1%, and 93.7% PPA and 98.2%, 96.9%, 96.6%, and 99.1% NPA compared to Cepheid Xpert C. difficile, BD MAX Cdiff, Verigene CDF, and BioFire GI panel, respectively. Overall, the QIAstat-Dx GIP 2 assay was accurate and comparable to other commercially available methods, and the short assay setup time offers an efficient laboratory stool testing workflow.IMPORTANCEClostridioides difficile infection ranges from diarrhea to severe, life-threatening pseudomembranous colitis. Clinical criteria include three or more liquid stools in 24 h, while diagnostic testing includes nucleic acid tests alone or in combination with an enzyme immunoassay for C. difficile antigen and toxin. This study evaluates the analytical performance of C. difficile detection from clinical specimens using the QIAstat-Dx multiplex gastrointestinal panel compared with four commercial assays (Cepheid Xpert C. difficile, BD MAX Cdiff, Verigene CDF assays, and BioFire GI panel) and a C. difficile immunoassay. The BioFire GI panel had the highest positive percent agreement (90-100%), followed by the QIAstat-Dx (88-98%), BD MAX (87-98%), and the Xpert assays (86-96%). The QIAstat-Dx demonstrated high positive and negative agreement with all nucleic acid tests. The short assay setup time for the QIAstat-Dx GIP 2 also offers a streamlined testing workflow.
引用
- Sabharwal L, Purpora A, Gerstbrein D, et al. Performance evaluation of the QIAstat-Dx gastrointestinal panel 2 for the detection of Clostridioides difficile against multiple commercial assays. J Clin Microbiol. 2025. PMID: 41117599. doi:10.1128/jcm.00576-25
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。